New Phase 3 Data on Baricitinib Efficacy in Atopic Dermatitis
February 4, 2020
Baricitinib (Olumiant, Eli Lilly and Incyte) demonstrated positive results in the BREEZE-AD5 study of patients with atopic dermatitis.
Atopic Dermatitis
FDA Grants Priority Review to Dupilumab for Children with Atopic Dermatitis
January 28, 2020
If approved, dupilumab (Dupixent, Regeneron and Sanofi) would be indicated for use as an add-on maintenance treatment for children ages 6 to 11 years with moderate-to-severe atopic dermatitis.
